BioTech IP Review

Publication Number: US 20250321446 A1
Filing Date: February 26, 2025 (earliest‑filed application)
Publication Date: January 13, 2026 (publication of the granted patent) 
Assignee / Applicant: Bristol‑Myers Squibb Company 

---

What This Covers

This patent relates to antibody‑drug conjugates (ADCs) targeting CEACAM5 (carcinoembryonic antigen‑related cell adhesion molecule 5) — a cell surface protein frequently overexpressed in several solid tumors, including colorectal, pancreatic, and lung cancers. The application claims:

• Antibody molecules that specifically bind CEACAM5.
• Cytotoxic payloads chemically linked to these antibodies to selectively deliver potent anti‑cancer drugs to tumor cells.
• Linker chemistries that stably attach the cytotoxic payload yet release it once inside the tumor cell.
• Methods of treating cancer by administering the ADC to subjects in need thereof.

In essence, the invention combines BMS’s targeting antibody with a powerful cell‑killing agent to improve efficacy and safety compared to conventional chemotherapies or unconjugated biologics.

---

Why This Is Important

1) Strong commercial relevance in oncology:
Antibody‑drug conjugates are one of the fastest‑growing classes of cancer therapeutics, with multiple ADCs on the market generating billions in annual sales. CEACAM5 is a well‑validated tumor antigen, making it a high‑value target for next‑generation cancer treatments.

2) Pipeline and competitive positioning:
BMS has been actively expanding its oncology portfolio, and patents on novel ADCs can yield market exclusivity, block competitors, and support high‑margin biologic drug sales.

3) Patent timing:
This application connects it directly to BMS’s ongoing R&D output and forthcoming commercial assets. Securing broad claims now can protect future products once they reach late‑stage trials.